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Abstract
Between 2003 and 2008, 76 clinical isolates of the Panton–Valentine leukocidin-positive Staphylococcus aureus strain ‘West Australian
methicillin-resistant Staphylococcus aureus (MRSA)-12’ (WA MRSA-12) were recovered from 72 patients living in the Perth area in
Western Australia. These isolates were found to belong to multilocus sequence type 8, and had a USA300-like pulsed-ﬁeld gel electro-
phoresis pulsotype. All isolates were genotyped using diagnostic DNA arrays covering species markers, resistance factors, virulence-
associated, as well as MSCRAMM (microbial surface components recognizing adhesive matrix molecules) genes to prove the identity
between WA MRSA-12 and the pandemic strain USA300, as well as to detect possible genetic variability. In general, WA MRSA-12
isolates were similar to USA300, and the most common variant was identical to USA300-TC1516. From this clone, most of the other
variants may have evolved by a limited number of gene losses or acquisitions. Variations in carriage of virulence and resistance-associ-
ated genes allow distinction of variants or sub-clones. Altogether, 16 variants could be distinguished. They differed in the carriage of
resistance genes (blaZ/I/R, ermC, msrA + mpbBM, aadD + mupR, aphA3 + sat, tetK, qacC, merA/B/R/T) of b-haemolysin-converting phages
and of enterotoxins (sek + seq, which were deleted in four isolates). Notably, the arginine catabolic mobile element (ACME) was absent
in 12 isolates (15.8%). The mercury resistance (mer) operon, which is usually associated with SCCmec type III elements, was found in
several ACME-negative isolates. The present study emphasises the importance of genotyping in detecting the introduction and evolution
of signiﬁcant MRSA strains within a community.
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Introduction
In recent years, a pandemic unfolded of methicillin-resistant
Staphylococcus aureus (MRSA) strains that carry novel and
apparently highly mobile chromosomal staphylococcal chro-
mosomal cassette elements harbouring mecA (SCCmec
elements). Such strains have emerged outside the hospital
setting and have been designated as ‘community-associated
MRSA’ (CA-MRSA). Some of them harbour the prophage-
encoded [1,2] virulence factor Panton–Valentine leukocidin
(PVL). PVL is a bicomponent toxin that forms polymeric
pores in leukocyte membranes [3], although its role in path-
ogenesis is still subject to discussion [4–6]. Several PVL-posi-
tive CA-MRSA strains from different clonal groups have
evolved. Some have been conﬁned to certain regions or
localised outbreaks, whereas others have spread worldwide.
One of these strains, a clonal complex 8, spa type t008
MRSA carrying a SCCmec type IV element, has recently
emerged as the dominant MRSA strain in North America,
both in community and hospital settings [7–14]. Colloquially
known as USA300, it has also been reported from Australia,
Canada, Denmark, Germany, Japan, Switzerland and the UK
[10,15–18]. Because of its rapid spread, it has drawn consid-
erable attention, resulting in the sequencing of two complete
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.02792.x
genomes (USA300-FPR3757, GenBank CP000255.1 [19]
and USA300-TCH1516, CP000730.1 [20]). One remarkable
ﬁnding was the detection of an arginine catabolic mobile ele-
ment (ACME), which previously only has been found in
Staphylococcus epidermidis. It was hypothesised that ACME
contributed to the ability to metabolically alter the local pH
on the skin. This could increase the ability of USA300 to
persist on intact skin and, consequently, facilitate spread by
skin contact [19,21].
Locally known as WA MRSA-12, several USA300-like
isolates have been identiﬁed in Australia [22]. To determine
whether WA MRSA-12 was identical to USA300, we applied
previously developed DNA microarrays on a collection of
Australian PVL-positive ST8-MRSA IV isolates. Variations
detected within this strain may be relevant for typing or
therapeutic interventions.
Material and methods
Isolates and patients
Between July 2003 and February 2008, 76 MRSA isolates from
72 patients living in the Perth area, Western Australia (WA),
were characterised as PVL-positive WA MRSA-12 using
pulsed-ﬁeld gel electrophoresis (PFGE) [23] and PCR for the
detection of PVL genes using previously published primers
[24]. Representative PFGE patterns are shown in Fig. 1. MLST
and SCCmec typing were performed on 16 isolates (see Sup-
porting Information, Table S1) using previously published
methods [25–28]. Some 62.5% of the patients were male, and
approximately 55% were older than 30 years (Table S1).
Skin and soft tissue infections were reported in 94.4% of
cases. The remaining cases were asymptomatic, and sub-
jected to contact screening. Necrotising pneumonia was not
observed.
To determine the stability of variants, follow-up isolates
from individual patients were also characterised.
The sequenced strain USA300-FPR3757 was included
in the study. Although the second sequenced strain,
USA300-TCH1516, was not tested, a prediction of its
hybridisation proﬁle based on the published genome
sequence allowed a comparison to be made with the WA
isolates.
Array procedures
The DNA array used in the present study covers 334
target sequences. Depending on the nomenclature used,
this corresponds to approximately 185 distinct genes and
their allelic variants, and includes mainly clinically relevant
genes on mobile elements that are not covered by whole-
genome arrays derived from sequenced genomes [29].
The targets, related protocols, data interpretation and evalu-
ation procedures used have been described previously
[30,31].
Brieﬂy, cultures were grown overnight on Columbia blood
agar. Culture material was harvested, lysed using lysostaphin,
lysozyme and ribonuclease A and treated with proteinase K.
DNA was puriﬁed using the Qiagen device EZ1 (Qiagen,
Valencia, CA, USA) according to the manufacturer’s tissue
lysis protocol. An iterated, linear primer elongation was
employed for the simultaneous ampliﬁcation of all targets.
Within this step, amplicons were labelled by incorporation of
biotin-16-dUTP.
The labelled sample was denatured and hybridised to the
array. This was followed by washing steps and by the addi-
tion of a blocking reagent. Horseradish–peroxidase–strepta-
vidin conjugate was then added to the array, followed by
incubation and washing. The array tube was placed into the
ATR01 reading device (Clondiag, Jena, Germany), and Sera-
mun Green precipitating dye (Seramun, Heidesee, Germany)
FIG. 1. Pulsed-ﬁeld gel electrophoresis pat-
terns of representative USA300 isolates from
the Perth area and their afﬁliations to variants
based on array hybridisations.
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was added. After 5 min, an image of the array was recorded
and analysed.
Results
Virulence-associated genes and the ACME locus
Array hybridisation and PCR [24] demonstrated that all WA
MRSA-12 isolates harboured the PVL genes, lukF-PV and
lukS-PV.
All but four isolates (94.7%) yielded hybridisation signals
for enterotoxin genes sek and seq. Negative results were
conﬁrmed by PCR (primers sek_forward, ACAGAGAATTT
TCATTTGGATGT and sek_reverse, CACATTTTGCTTAT
CCCTCCT, with a melting temperature during PCR of
55C, as well as primers seq_forward_2 GCTTCAAGGAGT
TAGTTCTGG and seq_reverse_2 CTTGACCAGTTCCGG
TGT, with a melting temperature of 54C; see Supporting
Information, Table S1).
One isolate was negative for genes encoding staphylokin-
ase (sak), chemotaxis-inhibiting protein (chp) and staphylo-
coccal complement inhibitor (scn). Two isolates were
positive for sak and scn, but lacked chp. Carriage of set/ssl
genes was identical to USA300-FPR3757 and USA300-
TCH1516 genome sequences and to previously described
USA300 isolates from Germany [30].
Genes of the ACME locus (arcA-SCC, arcB-SCC, arcC-SCC
and arcD-SCC) were detected in 64 (84.2%) of the WA
MRSA-12 isolates. An absence of ACME was conﬁrmed using
two different arcA PCRs [19,32].
Capsule, bioﬁlm and microbial surface components recog-
nizing adhesive matrix molecules (MSCRAMM) genes
Carriage of capsule genes (type 5), bioﬁlm (icaA, icaC, icaD)
and MSCRAMM genes (bbp, clfA, clfB, ebh, ebpS, eno, ﬁb, fnbA,
fnbB, map, sdrC, sdrD and vwb) was identical to USA300-
FPR3757 and USA300-TCH1516.
Antibiotic resistance determinants
Apart from one isolate, all WA MRSA-12 isolates carried
mecA as a part of the SCCmec type IV element. This isolate
initially did not yield hybridisation signals for any of the
SCCmec-associated genes.
However, growth on a broth containing cefoxitin was
observed. DNA from this culture yielded signals for mecA
and all other SCCmec type IV probes (ugpQ, crrA-2, crrB-2,
truncated mecR). Except for these markers, the hybridisation
pattern remained unchanged and allowed assignment to var-
iant L (Figure 2).
The b-lactamase operon (blaZ, blaI, blaR), a gene encoding
a putative transport protein (SAUSA300_2128, USA300-
HOU_2160), and the fosfomycin resistance gene fosB
(SAUSA300_2280, USA300HOU_2313) were detected in all
isolates.
The neo-/kanamycin resistance gene aphA3 and the strep-
tothricin resistance gene sat were jointly detected in 64
(84.2%) isolates. Two genes for macrolide efﬂux proteins,
msrA and mpbBM were also always found together in 61
(80.3%) isolates.
Comparatively rare resistance determinants included the
rRNA adenine N-6-methyltransferase gene ermC (in seven
isolates, 9.2%), a gene for a tetracycline efﬂux protein, tetK
(eight isolates, 10.5%), a gene encoding an unspeciﬁc efﬂux
pump (qacC, one isolate, 1.3%), as well as the aminoglycoside
adenyltransferase gene aadD and a gene conferring high level
mupirocin resistance, mupR (two isolates, 2.6%). In WA
MRSA-12 isolates, aadD and mupR genes occurred together,
whereas, in USA300-FPR3757, only mupR was present.
MsrA/mpbBM or ermC were mutually exclusive in all
isolates but one.
The mer operon
The genes merA (encoding mercuric reductase), merB (orga-
nomercurial lyase), merR (regulatory protein) and merT
(transport protein) were detected in eight (10.5%) isolates,
with all of them being ACME-negative.
Variants of the WA MRSA-12 strain
Hybridization proﬁles identiﬁed 16 variants (variants A–P,
Fig. 2) among 76 WA MRSA-12 isolates. Forty-seven isolates
(61.8%) belonged to variant A. An analysis of the genome
sequence of USA300-TCH1516 predicted the same hybrid-
isation pattern as that observed in variant A. Strain CDC
2001-5114, which was used as reference for PFGE, repre-
sents a seventeenth variant. It differed from variant A only in
being tetK-positive. Thus, ‘USA300’ and ‘WA MRSA-12’ can
be regarded as synonyms for one strain. An eighteenth vari-
ant is represented by USA300-FPR3757. Its hybridisation
pattern was in full accordance with a prediction based on its
genome sequence. No clinical isolates of this variant were
found in WA.
To assess the stability of variants, attention focused on
follow-up isolates from individual patients and on isolates
from family members (Table S1). Identical follow-up isolates
from individual cases were recovered after 3, 76 and
580 days. In one case, a patient initially infected with variant
A cultured a follow-up isolate after 205 days, which differed
in the presence of aadD and mupR (variant G).
772 Clinical Microbiology and Infection, Volume 15 Number 8, August 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 770–776
In three separate episodes, USA300 was isolated from
family members. In one case, a girl was diagnosed with a
variant I infection, 295 days after the same variant was
recovered from her mother. In another case, two isolates
of variant A were sampled within 1 month from two
siblings.
In a third family, both parents and their two children
were, within a period of 7 months, infected with variant A.
Discussion
USA300 is a PVL-positive, CA-MRSA strain that has spread
rapidly in North America. Sporadic cases and outbreaks have
been reported from various European countries and in
Australia. In WA, the ﬁrst infection with USA300/WA
MRSA-12 was reported in 2003. Subsequently, an increase in
the number of cases has occurred, particularly within 2007
and in 2008 (Fig. 3).
USA300 isolates were not identical to each other. Thus,
USA300 cannot be regarded as a genetically homogenous
unit. Whether, for example, ACME-positive and -negative
isolates should be regarded as variants of one strain, or as
two different strains, is a matter of deﬁnition, raising the
question of how to deﬁne a strain in general and USA300 in
particular. Variations within USA300 affected virulence
factors and antibiotic resistance determinants. MSCRAMM,
capsule or set/ssl gene carriage was uniform, and closely
resembled the other clonal complex 8 strains [30], including
NCTC8325 [33]. It can be assumed that the lack of variabil-
ity of these genes was due to the relatively short time-span
of USA300 proliferation, whereas virulence- and resistance-
associated genes varied on a faster time-scale because they
are situated on mobile elements.
FIG. 2. Variants of clinical West Austra-
lian MRSA-12 isolates. Experimental data
for the sequenced strain USA300-
FPR3757 and for strain CDC 2001-5114
(which was used as reference strain for
pulsed-ﬁeld gel electrophoresis experi-
ments), as well as the predicted hybrid-
isation proﬁle for the sequenced strain
USA300-TCH1516, are shown for
comparison.
FIG. 3. Number of isolates per 3 mont-
hs interval. Black, West Australian MRS-
A-12 variant A; Grey, isolates of other
ACME-positive variants; White, ACME-
negative isolates; asterisk, January and
February only.
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One isolate lacked the phage-born innate immune evasion
cluster (which truncates the hlb gene by introducing sak, chp
and scn [34,35]), and some isolates were negative for sek and
seq. Because ST80-MRSA IV also lacks enterotoxin genes
[36], it could be speculated that, for PVL-positive strains,
some virulence factors were expendable without selective
disadvantage.
Carriage of ACME was also variable. This is especially
intriguing because this locus is assumed to be involved in
facilitating the spread of USA300 by skin contact [19,21].
ACME-negative variants of USA300 appear to be common in
WA. They also exist in the USA but appear to be extremely
rare (one study found none [37] and another identiﬁed a
single isolate [38]), and they have been reported in Germany
[39]. Thus, they are not restricted to WA, and a strategy to
identify USA300 by multiplex PCR detection of PVL, mecA
and ACME can conﬁrm, but not rule out, the presence of
USA300. Because of the limited time of the presence of
USA300 in WA, further studies should focus on possible
changes of the ratio of ACME-positive to -negative variants.
This may improve our understanding of the clinical signiﬁ-
cance of this element and its proposed role in the rapid
spread of USA300.
The variability of resistance genes was not unexpected
because these genes are subjected to a high, but variable
selective pressure.
In one isolate, negative signals for SCCmec probes were
observed but, after passage on a cefoxitin-containing medium,
the resulting culture was positive for these genes. We assume
that a majority of cells lost the SCCmec element, but that a
small mecA-positive subpopulation below the detection limit of
linear ampliﬁcation was still present. In the presence of cefoxi-
tin, this subpopulation had a selective advantage resulting in
displacement of the deletion variant. A loss of SCCmec ele-
ments from MRSA has occasionally been observed [40–42],
emphasising the mobility of the SCCmec gene cluster.
Other common, but variable resistance genes included the
b-lactamase operon and a ﬁxed combination of sat and
aphA3. The latter genes are frequently detected in diverse
MRSA strains, including ST8-MRSA IV, ST45-MRSA IV, ST80-
MRSA IV and ST228-MRSA I [30]. Because neomycin is com-
monly used as topical preparation, aphA3 might confer an
advantage to a strain usually associated with skin infections.
Another apparently ﬁxed combination of resistance genes
comprised aadD and mupR, encoding resistance to neomycin,
tobramycin and mupirocin. Although mupR was rare, it
deserves further attention because mupirocin is crucial for
the eradication of MRSA. Macrolide resistance genes were
common. The genes msrA/mpbBM or ermC, apart from a sin-
gle exception, proved to be mutually exclusive. This might
indicate that the maintenance of multiple genes conferring
similar resistance properties could result in an unnecessary
ﬁtness cost. Because ermC encodes not only macrolide, but
also clindamycin resistance, it might confer a more signiﬁcant
advantage. In other MRSA strains, erm genes are more abun-
dant than msrA [43] but, in USA300, msrA/mpbBM positive
isolates predominate. Thus, clindamycin can be considered as
therapeutic option, although a widespread application might
favour ermC positive variants of USA300.
Surprisingly, the mercury resistance (mer) operon was
found in ACME-negative USA300 isolates. It can be plasmid-
borne (GenBank L29436) but, similar to ACME, it can also
be associated with recombinases (GenBank AB037671, [44])
forming some kind of SCC element. Thus, its genetic back-
ground and its position in the USA300 genome remains to
be clariﬁed.
Further isolates from diverse regions and over a longer
time-span need to be studied to determine whether the
described variability represents random variations, or an
early stage of a rift into separate strains. It will also be inter-
esting to observe the competition of variants which are—
except for a small number of genes—essentially isogenic. An
especially successful variant can be expected to combine
genetic traits that also are responsible for the success of
USA300, regardless of whether this might be the carriage of
PVL, ACME [19,21] or another factor yet to be identiﬁed. In
the present study, variant A appeared to be most successful.
Because it was the ﬁrst USA300 variant detected in WA, it
can be regarded as the founder variant, from which variants
B–L, and possibly M, may have been derived by a limited
number of gene losses or acquisitions. Variant A appears to
be geographically widespread because it has been found in
Texas (USA300-TC1516), in the German states Saxony
[16,30] and Brandenburg, and in Switzerland (isolates cour-
tesy of T. Juratzek and B. Berger-Baechi).
The explosive expansion of USA300 still warrants further
study. DNA microarray technology might contribute to the
understanding of this phenomenon by resolving variants
below strain level. This might be helpful for tracing chains of
transmissions and elucidating the sources of importation of
that strain into a given region.
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